Takeda informed the World Federation of Hemophilia (WFH) that this decision was made due to the fact that people with bleeding disorders (PWBDs) are transitioning to alternative therapies, including those within Takeda’s own hematology portfolio. The company further emphasized that the discontinuation is not due to quality or safety concerns, as both products remain effective and meet regulatory standards.
The WFH is aware that transitioning to other products can be challenging. Takeda stated that they are actively reaching out to healthcare professionals (HCPs) and WFH national member organizations (NMOs) in affected countries to support the transition. The company will continue supplying the products to current patients until inventory runs out or expires by mid-2026, with exact timing dependent on demand and product potency. Alternate therapies should be able to meet the demand for HEMOFIL M and RECOMBINATE, and we hope our community members will be able to transition to those treatments as soon as possible.
NMOs who wish to know more—or who need further support transitioning from HEMOFIL M and RECOMBINATE—are encouraged to contact their WFH Regional Manager. PWBDs who have concerns should contact their NMO.
To find out more, please read the full letter by Takeda here.